Gastronomic delicacies in Paris

In our second ESMO 2022 Preview we take a look at some of the key trials being presented in gastrointestinal cancers and highlight what to watch out for on this front.

While a few readers will no doubt be keen to skip to the KRAS section to learn more about sotorasib and adagrasib in colorectal cancer, make no mistake there’s plenty going on in new product development in several other GI cancers too, both with targeted therapies as well as immunotherapies.

Curious to learn more?

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by